Investment Thesis
On valuation grounds relative to the current share price, SHL trades fair value.
- As the Covid pandemic subsides, near-term earnings may underwhelm but in the longer term, there’s no doubt that the quality of SHL’s assets, which is geographically diversified and high-quality management team.
- The Aging population requires more diagnostic tests, especially as Medicine focuses on preventative medicine.
- Market leading positions in pathology (number one in Australia, Germany, Switzerland, and UK number three in the US). Second leading player in Imaging in Australia.
- High barriers to entry in establishing global channels.
- Ongoing bolt-on acquisitions to supplement organic growth and potentially improve margin from cost synergies.
- Leveraged to a falling dollar.
- Globally diversified.
Key Risks
- Disruptive technology leading to reduced diagnostics costs.
- Competitive threats leading market share loss.
- Deregulation resulting in new pathology collection centres.
- Adverse regulatory changes (fee cuts).
- Disappointing growth.
- Adverse currency movements (AUD, EUR, USD).
Key Highlights: Relative to the pcp and on a constant currency basis:
- Base business (ex-Covid testing) revenue of $3,703m, was up +9% versus the pcp or up +11% versus the pre-pandemic 1H20. Base business revenue (ex-Covid testing) organic growth was +6% versus 1H22 and +8% versus 1H20 (constant currency, per working day). SHL’s management noted “growth gaining momentum with January 2023 versus January 2020 revenue up 10%, particularly strong in Australian Pathology division”. Base business margins were in line with pre-pandemic levels.
- Covid-19 revenue of $379m, represents a decline of -72%.
- Total revenue of $4,082m, was down -14% versus the pcp or up +22% versus the prepandemic 1H20.
- EBITDA of $920m was down -40% versus the pcp or up +33% versus the pre-pandemic 1H20.
- Net profit of $382m was down -54% versus the pcp or up 47% versus the pre-pandemic 1H20. Earnings per share was up +52% versus 1H20 (pre-pandemic).
- SHL’s gearing level are close to historic lows, with ~A$1.5bn of available liquidity, well positioned to fund growth, with the Company currently progressing several acquisition and contract opportunities.
Company Description
Sonic Healthcare (SHL) is a medical diagnostics company with operations in Australia, New Zealand, and Europe. The company provides a comprehensive range of pathology and diagnostic imaging services to medical practitioners, hospitals and their patients along with providing administrative services and facilities to medical practitioners. SHL has three main segments: (1) Pathology/clinical laboratory services based in Australia, NZ, UK, US, Germany, Switzerland, Belgium and Ireland. (2) Diagnostic imaging services in Australia; and (3) Other which includes medical centre operations (IPN), occupational health services (Sonic Health Plus) and laboratory automation development (GLP Systems).
DISCLAIMER for General Advice: (This document is for general advice only).
This document is provided by Laverne Securities Pty Ltd T/as Investor Desk. Laverne Securities Pty Ltd, CAR 001269781 of Laverne Capital Pty Ltd AFSL No. 482937.
The material in this document may contain general advice or recommendations which, while believed to be accurate at the time of publication, are not appropriate for all persons or accounts. This document does not purport to contain all the information that a prospective investor may require. The material contained in this document does not take into consideration an investor’s objectives, financial situation or needs. Before acting on the advice, investors should consider the appropriateness of the advice, having regard to the investor’s objectives, financial situation, and needs. The material contained in this document is for sales purposes. The material contained in this document is for information purposes only and is not an offer, solicitation or recommendation with respect to the subscription for, purchase or sale of securities or financial products and neither or anything in it shall form the basis of any contract or commitment. This document should not be regarded by recipients as a substitute for the exercise of their own judgment and recipients should seek independent advice.
The material in this document has been obtained from sources believed to be true but neither Investor Desk and Banyan Tree nor its associates make any recommendation or warranty concerning the accuracy or reliability or completeness of the information or the performance of the companies referred to in this document. Past performance is not indicative of future performance. Any opinions and or recommendations expressed in this material are subject to change without notice and, Investor Desk and Banyan Tree are not under any obligation to update or keep current the information contained herein. References made to third parties are based on information believed to be reliable but are not guaranteed as being accurate.
Investor Desk and Banyan Tree and its respective officers may have an interest in the securities or derivatives of any entities referred to in this material. Investor Desk and Banyan Tree do and seek to do, business with companies that are the subject of its research reports. The analyst(s) hereby certify that all the views expressed in this report accurately reflect their personal views about the subject investment theme and/or company securities.
Although every attempt has been made to verify the accuracy of the information contained in the document, liability for any errors or omissions (except any statutory liability which cannot be excluded) is specifically excluded by Investor Desk and Banyan Tree, its associates, officers, directors, employees, and agents. Except for any liability which cannot be excluded, Investor Desk and Banyan Tree, its directors, employees and agents accept no liability or responsibility for any loss or damage of any kind, direct or indirect, arising out of the use of all or any part of this material. Recipients of this document agree in advance that Investor Desk and Banyan Tree are not liable to recipients in any matters whatsoever otherwise; recipients should disregard, destroy or delete this document. All information is correct at the time of publication. Investor Desk and Banyan Tree do not guarantee reliability and accuracy of the material contained in this document and is not liable for any unintentional errors in the document.
The securities of any company(ies) mentioned in this document may not be eligible for sale in all jurisdictions or to all categories of investors. This document is provided to the recipient only and is not to be distributed to third parties without the prior consent of Investor Desk and Banyan Tree.